Engineering endostatin-producing cartilaginous constructs for cartilage repair using nonviral transfection of chondrocyte-seeded and mesenchymal-stem-cell-seeded collagen scaffolds

Tissue Engineering - Part A

Volumn 16, Issue 10, 2010, Pages 3011-3021

  Jeng, Lily ^a,b   Olsen, Bjorn R ^c   Spector, Myron ^a,d  

^a VA BOSTON HEALTHCARE SYSTEM   (United States)

^b Massachusetts Institute of Technology Cambridge   (United States)

^c HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BODY FLUIDS; CARTILAGE; CELL CULTURE; COLLAGEN; ENGINEERS; LIGAMENTS; MICROBIOLOGY; OXYGEN; REPAIR; STEM CELLS; TISSUE ENGINEERING;

ANGIOGENESIS; ANTIANGIOGENIC FACTORS; ARTICULAR CARTILAGES; CARTILAGE REPAIR; CHONDROCYTES; CHONDROGENESIS; CHONDROGENIC; CHONDROGENIC POTENTIAL; COLLAGEN SCAFFOLDS; CULTURE MEDIUM; ENDOSTATINS; EXTERNAL FACTORS; LOW LEVEL; MESENCHYMAL STEM CELL; NONVIRAL; NONVIRAL VECTORS; OVER-EXPRESSION; OXYGEN TENSION; REGULATORY CONTROL; TIME POINTS; TISSUE REPAIR;

SCAFFOLDS;

COLLAGEN; ENDOSTATIN; TISSUE SCAFFOLD;

ANIMAL; ARTICLE; CARTILAGE; CARTILAGE CELL; CELL CULTURE; CHEMISTRY; CYTOLOGY; GOAT; IMMUNOHISTOCHEMISTRY; MESENCHYMAL STEM CELL; METABOLISM; METHODOLOGY; TISSUE ENGINEERING;

ANIMALS; CARTILAGE; CELLS, CULTURED; CHONDROCYTES; COLLAGEN; ENDOSTATINS; GOATS; IMMUNOHISTOCHEMISTRY; MESENCHYMAL STEM CELLS; TISSUE ENGINEERING; TISSUE SCAFFOLDS;

EID: 77957672518     PISSN: 19373341     EISSN: 1937335X     Source Type: Journal    
DOI: 10.1089/ten.tea.2009.0771     Document Type: Article

References (19)

1. Fenwick, S.A., Gregg, P.J., and Rooney, P. Osteoarthritic cartilage loses its ability to remain avascular. Osteoarthritis Cartilage 7, 441, 1999.
2. Ashraf, S., and Walsh, D.A. Angiogenesis in osteoarthritis. Curr Opin Rheumatol 20, 573, 2008.
3. Kubo, S., Cooper, G.M., Matsumoto, T., Phillippi, J.A., Corsi, K.A., Usas, A., Li, G., Fu, F.H., and Huard, J. Blocking vascular endothelial growth factor with soluble Flt-1 improves the chondrogenic potential of mouse skeletal muscle-derived stem cells. Arthritis Rheum 60, 155, 2009.
4. Sun, X.-D., Jeng, L., Bolliet, C., Olsen, B.R., and Spector, M. Non-viral endostatin plasmid transfection of mesenchy-mal stem cells via collagen scaffolds. Biomaterials 30, 1222, 2009.
5. Stevens, M.M., Marini, R.P., Schaefer, D., Aronson, J., Lan-ger, R., and Shastri, V.P. In vivo engineering of organs: the bone bioreactor. Proc Natl Acad Sci\USA 102, 11450, 2005.
6. O'Reilly, M.S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W.S., Flynn, E., Birkhead, J.R., Olsen, B.R., and Folk-man, J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88, 277, 1997.
7. Feng, Y., Wu, Y.P., Zhu, X.D., Zhang, Y.H., and Ma, Q.J. Endostatin promotes the anabolic program of rabbit chon-drocyte. Cell Res 15, 201, 2005.
8. Pufe, T., Petersen, W.J., Miosge, N., Goldring, M.B., Men-tlein, R., Varoga, D.J., and Tillmann, B.N. Endostatin/collagen XVIII\an inhibitor of angiogenesis\is expressed in cartilage and fibrocartilage. Matrix Biol 23, 267, 2004.
9. Zhou, S.D., Cui, Z.F., and Urban, J.P.G. Factors influencing the oxygen concentration gradient from the synovial surface of articular cartilage to the cartilage-bone interface\a modeling study. Arthritis Rheum 50, 3915, 2004.
10. Nehrer, S., Breinan, H.A., Ramappa, A., Young, G., Short-kroff, S., Louie, L.K., Sledge, C.B., Yannas, I.V., and Spector, M. Matrix collagen type and pore size influence behaviour of seeded canine chondrocytes. Biomaterials 18, 769, 1997.
11. Samuel, R.E., Lee, C.R., Ghivizzani, S.C., Evans, C.H., Yannas, I.V., Olsen, B.R., and Spector, M. Delivery of plas-mid DNA to articular chondrocytes via novel collagen-glycosaminoglycan matrices. Hum Gene Ther 13, 791, 2002.
12. Capito, R.M., and Spector, M. Collagen scaffolds for nonvi-ral IGF-1 gene delivery in articular cartilage tissue engineering. Gene Ther 14, 721, 2007.
13. Pfeiffer, E., Vickers, S.M., Frank, E., Grodzinsky, A.J., and Spector, M. The effects of glycosaminoglycan content on the compressive modulus of cartilage engineered in type II collagen scaffolds. Osteoarthritis Cartilage 16, 1237, 2008.
14. Flint, M.H., Lyons, M.F., Meaney, M.F., and Williams, D.E. The Masson staining of collagen\an explanation of an apparent paradox. Histochem J 7, 529, 1975.
15. Kulke, M.H., Bergsland, E.K., Ryan, D.P., Enzinger, P.C., Lynch, T.J., Zhu, A.X., Meyerhardt, J.A., Heymach, J.V., Fogler, W.E., Sidor, C., Michelini, A., Kinsella, K., Venook, A.P., and Fuchs, C.S. Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J Clin Oncol 24, 3555, 2006.
16. Yamaguchi, N., Anand-Apte, B., Lee, M., Sasaki, T., Fukai, N., Shapiro, R., Que, I., Lowik, C., Timpl, R., and Olsen, B.R. Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding. EMBO J 18, 4414, 1999.
17. Ghafar, M.A., Anastasiadis, A.G., Olsson, L.E., Chichester, P., Kaplan, S.A., Buttyan, R., and Levin, R.M. Hypoxia and an angiogenic response in the partially obstructed rat bladder. Lab Invest 82, 903, 2002.
18. Wu, P., Yonekura, H., Li, H., Nozaki, I., Tomono, Y., Naito, I., Ninomiya, Y., and Yamamoto, H. Hypoxia down-regulates endostatin production by human microvascular endothelial cells and pericytes. Biochem Biophys Res Com-mun 288, 1149, 2001.
19. Dass, C.R. Cytotoxicity issues pertinent to lipoplex-mediated gene therapy in-vivo. J Pharm Pharmacol 54, 593, 2002.